{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T02:07:37Z","timestamp":1771466857492,"version":"3.50.1"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>OBJECTIVES:<\/jats:title>\n            <jats:p>Treatments that prevent sepsis complications are needed. Circulating lipid and protein assemblies\u2014lipoproteins play critical roles in clearing pathogens from the bloodstream. We investigated whether early inhibition of proprotein convertase subtilisin\/kexin type 9 (PCSK9) may accelerate bloodstream clearance of immunogenic bacterial lipids and improve sepsis outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DESIGN:<\/jats:title>\n            <jats:p>Genetic and clinical epidemiology, and experimental models.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>SETTING:<\/jats:title>\n            <jats:p>Human genetics cohorts, secondary analysis of a phase 3 randomized clinical trial enrolling patients with cardiovascular disease (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab [ODYSSEY OUTCOMES]; NCT01663402), and experimental murine models of sepsis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>PATIENTS OR SUBJECTS:<\/jats:title>\n            <jats:p>Nine human cohorts with sepsis (total <jats:italic toggle=\"yes\">n<\/jats:italic> = 12,514) were assessed for an association between sepsis mortality and <jats:italic toggle=\"yes\">PCSK9<\/jats:italic> loss-of-function (LOF) variants. Incident or fatal sepsis rates were evaluated among 18,884 participants in a post hoc analysis of ODYSSEY OUTCOMES. C57BI\/6J mice were used in <jats:italic toggle=\"yes\">Pseudomonas aeruginosa<\/jats:italic> and <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic> bacteremia sepsis models, and in lipopolysaccharide-induced animal models.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>INTERVENTIONS:<\/jats:title>\n            <jats:p>Observational human cohort studies used genetic <jats:italic toggle=\"yes\">PCSK9<\/jats:italic> LOF variants as instrumental variables. ODYSSEY OUTCOMES participants were randomized to alirocumab or placebo. Mice were administered alirocumab, a PCSK9 inhibitor, at 5\u2009mg\/kg or 25\u2009mg\/kg subcutaneously, or isotype-matched control, 48 hours prior to the induction of bacterial sepsis. Mice did not receive other treatments for sepsis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MEASUREMENTS AND MAIN RESULTS:<\/jats:title>\n            <jats:p>Across human cohort studies, the effect estimate for 28-day mortality after sepsis diagnosis associated with genetic <jats:italic toggle=\"yes\">PCSK9<\/jats:italic> LOF was odds ratio = 0.86 (95% CI, 0.67\u20131.10; <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.24). A significant association was present in antibiotic-treated patients. In ODYSSEY OUTCOMES, sepsis frequency and mortality were infrequent and did not significantly differ by group, although both were numerically lower with alirocumab vs. placebo (relative risk of death from sepsis for alirocumab vs. placebo, 0.62; 95% CI, 0.32\u20131.20; <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.15). Mice treated with alirocumab had lower endotoxin levels and improved survival.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS:<\/jats:title>\n            <jats:p>PCSK9 inhibition may improve clinical outcomes in sepsis in preventive, pretreatment settings.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cce.0000000000000997","type":"journal-article","created":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T17:04:39Z","timestamp":1699463079000},"page":"e0997","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacologic and Genetic Downregulation of Proprotein Convertase Subtilisin\/Kexin Type 9 and Survival From Sepsis"],"prefix":"10.1097","volume":"5","author":[{"given":"Patrick R.","family":"Lawler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garen","family":"Manvelian","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc., Tarrytown, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alida","family":"Coppi","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc., Tarrytown, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Damask","sequence":"additional","affiliation":[{"name":"Regeneron Genetics Center, Tarrytown, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael N.","family":"Cantor","sequence":"additional","affiliation":[{"name":"Regeneron Genetics Center, Tarrytown, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel A. R.","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Regeneron Genetics Center, Tarrytown, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Paulding","sequence":"additional","affiliation":[{"name":"Regeneron Genetics Center, Tarrytown, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilanjana","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Regeneron Genetics Center, Tarrytown, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dadong","family":"Li","sequence":"additional","affiliation":[{"name":"Regeneron Genetics Center, Tarrytown, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Jorgensen","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc., Tarrytown, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richa","family":"Attre","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc., Tarrytown, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Carey","sequence":"additional","affiliation":[{"name":"Department of Molecular and Functional Genomics, Geisinger Medical Center, Danville, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristi","family":"Krebs","sequence":"additional","affiliation":[{"name":"Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Milani","sequence":"additional","affiliation":[{"name":"Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristian","family":"Hveem","sequence":"additional","affiliation":[{"name":"K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Trondheim, Norway."},{"name":"HUNT Research Center, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Levanger, Norway."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan K.","family":"Dam\u00e5s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Sollig\u00e5rd","sequence":"additional","affiliation":[{"name":"Gemini Center for Sepsis Research, Department of Circulation and Medical Imaging, NTNU, Norwegian University of Science and Technology, Trondheim, Norway."},{"name":"Department of Medical Quality, M\u00f8re and Romsdal Hospital Trust, \u00c5lesund, Norway."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Stender","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Copenhagen University Hospital \u2013 Rigshospitalet, Copenhagen, Denmark."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Tybj\u00e6rg-Hansen","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Copenhagen University Hospital \u2013 Rigshospitalet, Copenhagen, Denmark."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00f8rge G.","family":"Nordestgaard","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Copenhagen University Hospital \u2013 Herlev Gentofte, University of Copenhagen, Copenhagen, Denmark."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Hernandez-Beeftink","sequence":"additional","affiliation":[{"name":"Research Unit, Hospital Universitario N.S. de Candelaria, Universidad de La Laguna, Santa Cruz de Tenerife, Spain."},{"name":"Research Unit, Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tormod","family":"Rogne","sequence":"additional","affiliation":[{"name":"Gemini Center for Sepsis Research, Department of Circulation and Medical Imaging, NTNU, Norwegian University of Science and Technology, Trondheim, Norway."},{"name":"Department of Chronic Disease Epidemiology and Center for Perinatal, Pediatric and Environmental Epidemiology, Yale School of Public Health, New Haven, CT."},{"name":"Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Flores","sequence":"additional","affiliation":[{"name":"Research Unit, Hospital Universitario N.S. de Candelaria, Universidad de La Laguna, Santa Cruz de Tenerife, Spain."},{"name":"CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain."},{"name":"Genomics Division, Instituto Tecnol\u00f3gico y de Energ\u00edas Renovables (ITER), Santa Cruz de Tenerife, Spain."},{"name":"Faculty of Health Sciences, University Fernando Pessoa Canarias, Las Palmas de Gran Canaria, Canary Islands, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Villar","sequence":"additional","affiliation":[{"name":"Research Unit, Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain."},{"name":"CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain."},{"name":"Li Ka Shing Knowledge Institute, St. Michael\u2019s Hospital, Toronto, ON, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith R.","family":"Walley","sequence":"additional","affiliation":[{"name":"Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent X.","family":"Liu","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Northern California, Division of Research, Oakland, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison E.","family":"Fohner","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Northern California, Division of Research, Oakland, CA."},{"name":"Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca A.","family":"Lotta","sequence":"additional","affiliation":[{"name":"Regeneron Genetics Center, Tarrytown, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos A.","family":"Kyratsous","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc., Tarrytown, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark W.","family":"Sleeman","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc., Tarrytown, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Scemama","sequence":"additional","affiliation":[{"name":"Sanofi, Chilly-Mazarin, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"DelGizzi","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc., Tarrytown, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Pordy","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc., Tarrytown, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie E.","family":"Horowitz","sequence":"additional","affiliation":[{"name":"Regeneron Genetics Center, Tarrytown, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aris","family":"Baras","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc., Tarrytown, NY."},{"name":"Regeneron Genetics Center, Tarrytown, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greg S.","family":"Martin","sequence":"additional","affiliation":[{"name":"Pulmonary, Allergy, Critical Care and Sleep Medicine, Emory University, Atlanta, GA."},{"name":"Grady Memorial Hospital, Atlanta, GA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe Gabriel","family":"Steg","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, INSERM U-1148 F75018 Paris, France and Assistance Publique-H\u00f4pitaux de Paris, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory G.","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of Colorado School of Medicine, Aurora, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Szarek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaun G.","family":"Goodman","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, University of Toronto, Toronto, ON, Canada."},{"name":"Li Ka Shing Knowledge Institute, St. Michael\u2019s Hospital, Toronto, ON, Canada."},{"name":"Division of Cardiology, Department of Medicine, St Michael\u2019s Hospital, Toronto, ON, Canada."},{"name":"Canadian VIGOUR Centre, Department of Medicine, University of Alberta, Edmonton, AB, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,11,8]]},"reference":[{"key":"R1-20240806","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3).","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"R2-20240806","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0140-6736(19)32989-7","article-title":"Global, regional, and national sepsis incidence and mortality, 1990-2017: Analysis for the Global Burden of Disease Study.","volume":"395","author":"Rudd","year":"2020","journal-title":"Lancet"},{"key":"R3-20240806","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.molmed.2014.01.007","article-title":"Why have clinical trials in sepsis failed?","volume":"20","author":"Marshall","year":"2014","journal-title":"Trends Mol Med"},{"key":"R4-20240806","doi-asserted-by":"crossref","first-page":"258ra143","DOI":"10.1126\/scitranslmed.3008782","article-title":"PCSK9 is a critical regulator of the innate immune response and septic shock outcome.","volume":"6","author":"Walley","year":"2014","journal-title":"Sci Transl Med"},{"key":"R5-20240806","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/CCM.0000000000003609","article-title":"Proprotein convertase subtilisin\/kexin type 9 inhibition and survival in sepsis: Causal inference through human genetics.","volume":"47","author":"Sklar","year":"2019","journal-title":"Crit Care Med"},{"key":"R6-20240806","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000442976","article-title":"Increased plasma pcsk9 levels are associated with reduced endotoxin clearance and the development of acute organ failures during sepsis.","volume":"8","author":"Boyd","year":"2016","journal-title":"J Innate Immun"},{"key":"R7-20240806","doi-asserted-by":"crossref","first-page":"10496","DOI":"10.1038\/s41598-018-28777-0","article-title":"Low-density lipoprotein (LDL)-dependent uptake of Gram-positive lipoteichoic acid and Gram-negative lipopolysaccharide occurs through LDL receptor.","volume":"8","author":"Grin","year":"2018","journal-title":"Sci Rep"},{"key":"R8-20240806","doi-asserted-by":"crossref","first-page":"10588","DOI":"10.1038\/s41598-019-46745-0","article-title":"Reduced proprotein convertase subtilisin\/kexin 9 (PCSK9) function increases lipoteichoic acid clearance and improves outcomes in Gram positive septic shock patients.","volume":"9","author":"Leung","year":"2019","journal-title":"Sci Rep"},{"key":"R9-20240806","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/CCM.0000000000003551","article-title":"Low low-density lipoprotein levels are associated with, but do not causally contribute to, increased mortality in sepsis.","volume":"47","author":"Walley","year":"2019","journal-title":"Crit Care Med"},{"key":"R10-20240806","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1194\/jlr.M076844","article-title":"Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice.","volume":"58","author":"Berger","year":"2017","journal-title":"J Lipid Res"},{"key":"R11-20240806","doi-asserted-by":"crossref","first-page":"aaf6814","DOI":"10.1126\/science.aaf6814","article-title":"Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study.","volume":"354","author":"Dewey","year":"2016","journal-title":"Science"},{"key":"R12-20240806","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S2213-2600(19)30368-6","article-title":"Sepsis-associated acute respiratory distress syndrome in individuals of European ancestry: A genome-wide association study.","volume":"8","author":"Guillen-Guio","year":"2020","journal-title":"Lancet Respir Med"},{"key":"R13-20240806","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa067373","article-title":"Vasopressin versus norepinephrine infusion in patients with septic shock.","volume":"358","author":"Russell","year":"2008","journal-title":"N Engl J Med"},{"key":"R14-20240806","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41586-018-0579-z","article-title":"The UK Biobank resource with deep phenotyping and genomic data.","volume":"562","author":"Bycroft","year":"2018","journal-title":"Nature"},{"key":"R15-20240806","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/ije\/dys095","article-title":"Cohort profile: The HUNT Study, Norway.","volume":"42","author":"Krokstad","year":"2013","journal-title":"Int J Epidemiol"},{"key":"R16-20240806","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1534\/genetics.115.178616","article-title":"Characterizing race\/ethnicity and genetic ancestry for 100,000 subjects in the genetic epidemiology research on adult health and aging (GERA) cohort.","volume":"200","author":"Banda","year":"2015","journal-title":"Genetics"},{"key":"R17-20240806","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1534\/genetics.115.178905","article-title":"Genotyping informatics and quality control for 100,000 subjects in the genetic epidemiology research on adult health and aging (GERA) cohort.","volume":"200","author":"Kvale","year":"2015","journal-title":"Genetics"},{"key":"R18-20240806","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"R19-20240806","doi-asserted-by":"crossref","first-page":"e0167676","DOI":"10.1371\/journal.pone.0167676","article-title":"Identification of the functional variant(s) that explain the low-density lipoprotein receptor (LDLR) GWAS SNP rs6511720 association with lower LDL-C and risk of CHD.","volume":"11","author":"Fairoozy","year":"2016","journal-title":"PLoS One"},{"key":"R20-20240806","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome.","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"R21-20240806","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S2213-2600(16)00046-1","article-title":"Genomic landscape of the individual host response and outcomes in sepsis: A prospective cohort study.","volume":"4","author":"Davenport","year":"2016","journal-title":"Lancet Respir Med"},{"key":"R22-20240806","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1164\/rccm.201608-1685OC","article-title":"Shared and distinct aspects of the sepsis transcriptomic response to fecal peritonitis and pneumonia.","volume":"196","author":"Burnham","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"R23-20240806","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S2213-2600(18)30287-X","article-title":"Heterogeneity and phenotypic stratification in acute respiratory distress syndrome.","volume":"6","author":"Lawler","year":"2018","journal-title":"Lancet Respir Med"},{"key":"R24-20240806","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1164\/rccm.201505-0876CI","article-title":"The central role of proprotein convertase subtilisin\/kexin type 9 in septic pathogen lipid transport and clearance.","volume":"192","author":"Walley","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"R25-20240806","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/SHK.0000000000000682","article-title":"Differential expression of PCSK9 modulates infection, inflammation, and coagulation in a murine model of sepsis.","volume":"46","author":"Dwivedi","year":"2016","journal-title":"Shock"},{"key":"R26-20240806","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jama.2018.14618","article-title":"Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: The EUPHRATES randomized clinical trial.","volume":"320","author":"Dellinger","year":"2018","journal-title":"JAMA"},{"key":"R27-20240806","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1097\/01.CCM.0000217961.75225.E9","article-title":"Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock.","volume":"34","author":"Kumar","year":"2006","journal-title":"Crit Care Med"},{"key":"R28-20240806","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1179\/joc.2001.13.Supplement-2.159","article-title":"Antibiotic induced endotoxin release and clinical sepsis: A review.","volume":"13 Spec No 1","author":"Holzheimer","year":"2001","journal-title":"J Chemother"},{"key":"R29-20240806","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ebiom.2018.11.032","article-title":"Impact of PCSK9 loss-of-function genotype on 1-year mortality and recurrent infection in sepsis survivors.","volume":"38","author":"Genga","year":"2018","journal-title":"EBioMedicine"},{"key":"R30-20240806","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11908-016-0544-7","article-title":"Understanding long-term outcomes following sepsis: Implications and challenges.","volume":"18","author":"Shankar-Hari","year":"2016","journal-title":"Curr Infect Dis Rep"},{"key":"R31-20240806","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1097\/01.CCM.0000120053.98734.2C","article-title":"Detailed cost analysis of care for survivors of severe sepsis.","volume":"32","author":"Lee","year":"2004","journal-title":"Crit Care Med"},{"key":"R32-20240806","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00134-021-06479-y","article-title":"Association between sepsis survivorship and long-term cardiovascular outcomes in adults: A systematic review and meta-analysis.","volume":"47","author":"Kosyakovsky","year":"2021","journal-title":"Intensive Care Med"},{"key":"R33-20240806","doi-asserted-by":"crossref","first-page":"e11578","DOI":"10.1097\/MD.0000000000011578","article-title":"The effects of statin therapy on mortality in patients with sepsis: A meta-analysis of randomized trials.","volume":"97","author":"Chen","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"R34-20240806","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jacc.2022.10.030","article-title":"PCSK9 inhibition during the inflammatory stage of SARS-CoV-2 infection.","volume":"81","author":"Navarese","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"R35-20240806","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1097\/CCM.0b013e318168ea3e","article-title":"Multicenter, randomized, controlled trials evaluating mortality in intensive care: Doomed to fail?","volume":"36","author":"Ospina-Tascon","year":"2008","journal-title":"Crit Care Med"},{"key":"R36-20240806","doi-asserted-by":"crossref","first-page":"e197229","DOI":"10.1001\/jamanetworkopen.2019.7229","article-title":"Association of surrogate decision-making interventions for critically ill adults with patient, family, and resource use outcomes: A systematic review and meta-analysis.","volume":"2","author":"Bibas","year":"2019","journal-title":"JAMA Netw Open"}],"container-title":["Critical Care Explorations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000000997","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:01:46Z","timestamp":1722988906000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000000997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":36,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/cce.0000000000000997","relation":{},"ISSN":["2639-8028"],"issn-type":[{"value":"2639-8028","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11]]}}}